USD 6.5 billion
Cystic Fibrosis Therapeutics Market Size, Share, and Growth Analysis
Cystic Fibrosis Therapeutics Market By Drug Class (CFTR Modulators, Pancreatic Enzyme Supplements), By Route Of Administration (Oral, Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2224 |
Region:
Global |
Published Date: February, 2025
Pages:
219
|Tables:
62
|Figures:
75
Format -
Cystic Fibrosis Therapeutics Market Insights
Cystic Fibrosis Therapeutics Market size was valued at USD 6.5 billion in 2023 and is poised to grow from USD 7.42 billion in 2024 to USD 21.31 billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).
One of the important factors boosting the demand for cystic fibrosis treatments during the forecast period is the rising prevalence of cystic fibrosis (CF) combined with the rising treatment rate. Furthermore, an increase in R&D financing by both private and governmental organizations, an increase in the number of projects performed by nonprofit organizations, and the availability of favorable reimbursement policies represent a few of the critical aspects projected to drive the marketplace in years to come.
Increased year-on-year patient growth results in increased demand for effective and efficient CF therapies. Cystic fibrosis Transmembrane Conductivity Regulator (CFTR) modulators, bronchodilators, mucolytic medications, anti-infective, antibiotics (oral, breathed in, or parents feeding formulae), anti-inflammatory medications, and pancreatic enzyme supplements are just a few of the readily accessible approved drug classes.
One of the critical aspects projected to drive market expansion is the increasing number of medication compositions in the pipelines of the leading players. Furthermore, a growing number of studies conducted to extend its target client base with its existing therapeutic portfolio is one of the market's drivers. Increasing R&D activities are projected to drive market expansion.
The presence of various charitable organizations such as CF Worldwide, Cystic Fibrosis Organization, Cystic Fibrosis Canada as well, South African Cystic Fibrosis confidence, and South African Cystic Fibrosis Organization, that are consistently involved in CF-related activities, is another important factor that can account for promoting growth of the cystic fibrosis therapeutics market. These organizations are investing large sums of money to find various therapies for CF and to assist major actors' research and development operations.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Oral drugs
Fastest Growth
Oral drugs
Growth Rate
14.1% CAGR
Global Cystic Fibrosis Therapeutics Market 2022-2030 ($ Bn)
Country Share for Asia Pacific Region- 2022 (%)
To get more reports on the above market click here to Buy The Report
Cystic Fibrosis Therapeutics Market Segments Analysis
Global Cystic Fibrosis Therapeutics Market is segmented by Drug Class, Route Of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-infectives, CFTR Modulators, Pancreatic enzyme Supplements, Mucolytics and Bronchodilators. Based on Route Of Administration, the market is segmented into Oral and Inhaled. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Global Cystic Fibrosis Therapeutics Market Analysis by Route of Administration
The oral category dominated the market's expansion in 2022 and is predicted to be the fastest-growing industry during the forecast period, 2023-2030, due to the ease and convenience of eating medications. If novel formulations of drugs that may be conveniently administered without the risk of invasive techniques become available, oral medication forms may lose market share to alternative form types, such as inhaled medications.
Global Cystic Fibrosis Therapeutics Market Analysis by Drug Class
The cystic fibrosis (CF) market revenue was driven by CFTR modulators in 2022 and is predicted to grow at the quickest rate during the forecast period, 2022-2030.This is explained by a rise in the treatment of CF using these medicines. These drugs are currently widely employed to treat CF, and more CFTR treatments are now being studied in clinical trials. The primary purpose of these drugs is to help people live longer lives.
Global Cystic Fibrosis Therapeutics Market By Route of Administration 2022 (%)
To get detailed analysis on other segments, Request For Free Sample Report
Cystic Fibrosis Therapeutics Market Regional Insights
Asia Pacific had the largest cystic fibrosis market share in 2022 and is further expected to continue the same during the forecast period. The number of patients within the area is increasing and the urban lifestyle becomes more popular. This, together with increased healthcare spending, will most likely drive the APAC market. Furthermore, China's cystic fibrosis market had the highest market share, while India's cystic fibrosis market is the fastest expanding in the area.
Europe is expected to grow at the fastest CAGR from 2022 to 2030, owing to a rise in cystic fibrosis prevalence. Rising government backing for creativity, as well as increased funding for programs to research and develop innovative CF therapies, are driving market expansion in this sector. The United Kingdom provides the most money because of the significant incidence of the illness in this part of the world. In addition, the UK cystic fibrosis market has the largest share of the market, while the nation of Germany's cystic fibrosis industry was also the region's fastest growing.
Global Cystic Fibrosis Therapeutics Market By Geography, 2022-2030
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Cystic Fibrosis Therapeutics Market Dynamics
Global Cystic Fibrosis Therapeutics Market Drivers
Increasing Prevalence of Cystic Fibrosis
- The primary driver of the cystic fibrosis therapeutics market is the increasing prevalence of cystic fibrosis, a genetic disorder that affects the respiratory, digestive, and reproductive systems. The disease is incurable and requires lifelong treatment, driving the demand for cystic fibrosis therapeutics.
Growing Demand for Personalized Medicine
- The growing trend toward personalized medicine is driving the development of targeted therapies for cystic fibrosis, which can improve treatment outcomes and reduce side effects. Personalized medicine approaches are also expected to drive the growth of the cystic fibrosis therapeutics market in the coming years.
Global Cystic Fibrosis Therapeutics Market Restraints
High Cost of Cystic Fibrosis Therapies
- The high cost of cystic fibrosis therapies, particularly new targeted therapies, is a major barrier to treatment access for many patients. This has led to concerns about the affordability of these drugs and the impact on healthcare systems.
Limited Patient Pool
- Cystic fibrosis is a rare disease, affecting a relatively small patient population. This has limited the commercial potential of cystic fibrosis therapeutics and may impact the development of new drugs.
Request Free Customization of this report to help us to meet your business objectives.
Cystic Fibrosis Therapeutics Market Competitive Landscape
The cystic fibrosis therapeutics market competition consists of respiratory device manufacturers as well as standalone cystic fibrosis therapeutics producers. New technical advancements, such as the use of artificial intelligence, will generate growth prospects for new market entrants. For example, NuvoAir, a Swedish health care firm, created a digital platform that allows customers to perform at-home lung function tests. Companies are battling for market share, particularly in nations with advanced technology such as the United Kingdom, Germany, and the United States. Acquisitions and cooperation amongst market participants to strengthen their position have occurred. This is projected to increase market competition over the projection period.
Top Players in Cystic Fibrosis Therapeutics Market
- Vertex Pharmaceuticals (USA)
- AbbVie (USA)
- Gilead Sciences (USA)
- Roche (Switzerland)
- Teva Pharmaceutical Industries (Israel)
- Mylan (now Viatris) (USA)
- Novartis AG (Switzerland)
- AstraZeneca (UK)
- Alaxia.
- Allergan (now part of AbbVie) (Ireland)
- Beyond Air Inc. (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck & Co. Inc. (USA)
- Alcresta Therapeutics Inc. (USA)
- Chiesi (Italy)
- Nestlé HealthScience (Switzerland)
- Pharmaxis Ltd. (Australia)
- PTC Therapeutics, Inc. (USA)
- Insmed, Inc. (USA)
- Grifols S.A. (Spain)
Recent Developments
- In May 2023, the Cystic Fibrosis Foundation announced the success of their $1 billion fund raise with the purpose of new treatment research for cystic fibrosis. The funding will support research into gene editing, gene therapy, and other promising new technologies.
- In April 2023, Vertex Pharmaceuticals announced that it has entered into a collaboration with CRISPR Therapeutics to develop gene editing therapies for cystic fibrosis. The collaboration will focus on developing CRISPR-based therapies that target the underlying genetic defects that cause cystic fibrosis.
- In March 2023, AbbVie announced that the FDA granted fast track designation to its investigational drug ABBV-555 for the treatment of cystic fibrosis. ABBV-555 is a small molecule corrector that is designed to target the G551D mutation, the second most common mutation that causes cystic fibrosis.
- In February 2023, Shionogi announced that the FDA granted orphan drug designation to its investigational drug SHP616 for the treatment of cystic fibrosis. SHP616 is a small molecule corrector that is designed to target the F508del mutation, the most common mutation that causes cystic fibrosis.
- In January 2023, Vertex Pharmaceuticals announced that the FDA approved Trikafta (elexacaftor/ivacaftor/tezacaftor), a triple combination therapy for the treatment of cystic fibrosis in patients 12 years of age and older. Trikafta is the first and only triple combination therapy for cystic fibrosis and has been shown to significantly improve lung function and quality of life in patients.
- In October 2021, Vertex Pharmaceuticals announced that the European Medicines Agency (EMA) had accepted the Marketing Authorization Application (MAA) for their investigational triple combination therapy for cystic fibrosis, VX-121/tezacaftor/ivacaftor.
- In August 2021, Vertex Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) for their triple combination therapy, Trikafta, for patients with cystic fibrosis ages 6 through 11 who have at least one F508del mutation.
Cystic Fibrosis Therapeutics Key Market Trends
- Growing demand for personalized medicine: As the understanding of the genetic basis of cystic fibrosis improves, there is a growing demand for personalized medicine that targets the specific mutations responsible for the disease. This trend is expected to continue in the coming years, as newer therapies are developed that target specific mutations.
- Increasing use of combination therapies: Combination therapies that target multiple mutations are becoming increasingly common in the treatment of cystic fibrosis. This is due to the fact that many patients have multiple mutations that contribute to the disease, and targeting multiple mutations can lead to better outcomes.
- Development of therapies for non-classic mutations: While much of the research in cystic fibrosis therapeutics has focused on the most common mutations, there is a growing interest in developing therapies for non-classic mutations. These mutations are less common but can still contribute to the disease, and therapies that target them could benefit a significant number of patients.
- Increasing focus on disease management: While there is still no cure for cystic fibrosis, there is an increasing focus on disease management and improving quality of life for patients. This includes the development of therapies that target specific symptoms of the disease, as well as the use of nutritional and respiratory therapies to improve lung function and overall health.
- Growing importance of patient advocacy: Patients and patient advocacy groups are playing an increasingly important role in the development and approval of new cystic fibrosis therapies. This is due in part to the fact that many of these therapies are expensive and may not be covered by insurance, making it difficult for patients to access them without support from advocacy groups and other organizations.
Cystic Fibrosis Therapeutics Market SkyQuest Analysis
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates and Analyzes the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our global cystic fibrosis therapeutics market analysis, one of the important factors expected to drive demand for these treatments is the rising prevalence of cystic fibrosis (CF) combined with the rising treatment rate. Furthermore, an increase in R&D financing by both private and governmental organizations, an increase in the number of projects performed by nonprofit organizations, and the availability of favorable reimbursement policies represent a few of the critical aspects projected to drive the marketplace in years to come.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 6.5 billion |
| Market size value in 2032 | USD 21.31 billion |
| Growth Rate | 14.1% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Cystic Fibrosis Therapeutics Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Cystic Fibrosis Therapeutics Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Cystic Fibrosis Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cystic Fibrosis Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cystic Fibrosis Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cystic Fibrosis Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Cystic Fibrosis Therapeutics Market Report Snapshots
REQUEST FOR SAMPLE
Want to customize this report?
REQUEST FREE CUSTOMIZATION
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
